太阳2娱乐下载 > 西医西药 > 2006-2007 Annual Report on the Development of China's Bio-Pharmaceutical Indust

2006-2007 Annual Report on the Development of China's Bio-Pharmaceutical Indust

2020/01/28 11:06

中中原人民共和国报告网提醒:Research 田野s: bio-Pharmaceutical, product brands, channels, and technologiesEnterprises involved: Tiantan Pharmaceuticals, Novo Nordisk, Tongrentang, Tianhe Pharmaceuticals, Neptunus, HPGC, Xi'an YanssenReport HighlightsIn 二零零七, C

Research fields: bio-Pharmaceutical, product brands, channels, and technologiesEnterprises involved: Tiantan Pharmaceuticals, Novo Nordisk, Tongrentang, Tianhe Pharmaceuticals, Neptunus, HPGC, Xi'an Yanssen Report Highlights In 2006, China's bio-pharmaceutical industry grew steadily by some 15%. Biopharmaceutical enterprises' revenue rose sharply but the growth of profits evidently slowed down. Competition shifted to new technologies and new fields. As large enterprises pressed ahead with their internationalization process, the RD outsourcing market where SMEs play a leading role experienced remarkable growth. The growth of therapeutic drugs outstrips that of diagnosis drugs. Interferon, EPO, CSF, recombinant human insulin, and genetic engineering vaccine for Hepatitis B are still playing a leading role in the market. With the promulgation of relevant policies, in 2006 and 2007, target identification, animal and plant breed and drug molecular design, genetic manipulation, protein engineering, human tissue engineering based on stem cells and new-generation industrial biotechnology will see rapid development and are likely to become mainstream in the market. In the face of competition and changes and challenges in the market, CCID Consulting releases the 2006-2007 Annual Report on the Development of China's Bio-Pharmaceutical Industry, which helps vendors, investors, and industry chain grasp the pulse of China's bio-pharmaceutical industry in the following aspects, and comb the development course of segment application value - Backed by accurate market description data, the report depicts the development of the industry in 2006 from various angles, e.g. industry structure, research and development, production and manufacturing, raw materials, regional distribution, distribution channels, and price factors, to discern the industry's development trend.In briefly analyzing major brands' competition performance in 2006, it sums up enterprises' successes and failures in the dimension of shares of market segments, competition situation, and competition strategy, and reviews the makings of leading players. After presenting in-depth quantitative forecast of the market, it conducts modeling regression and expert verification for the whole market and market segments, and obtains valuable trend analysis and quantitative results. Moreover, it examines impetuses and obstacles to market segments, and conducts multidimensional analysis of user demand.

中原报告网提示:Research 田野同志s: bio-Pharmaceutical, product brands, channels, and technologiesEnterprises involved: Tiantan Pharmaceuticals, Novo Nordisk, Tongrentang, Tianhe Pharmaceuticals, Neptunus, HPGC, Xi'an YanssenReport HighlightsIn 二〇〇五, C

上一篇:2006-2007 Annual Report on the Development of China's Medical Industry太阳2娱乐下载: 下一篇:太阳2娱乐下载2012-2016年中国农药产业发展格局与投资方向研究报告